Potassium-competitive acid blocker
Abstract
Although the first-line medicine for the treatment of reflux esophagitis (RE) is proton. pomp inhibitor(PPI), the effectiveness is affected by the internal metabolism of PPI, the polymor- phism of metabolized enzyme for PPI, the presence of H. pyloi infection or esophageal hernia, and the grade of RE. Recent study indicates that about 30 % of severe RE is not healed after PPI treatment. Vonoprazan, potassium-competitive acid blocker(P-CAB), is effective for severe RE by the adequate control of gastric acidity including night-time and the day 1 after administration of Vonoprazan, comparing to current PPIs. On the other hand, Vono- prazan may cause hypergastrinemia, and the long-term follow-up is required to evaluate the adverse events for Vonoprazan.
Read the paper
Related studies
- Contribution of social science to large scale biodiversity conservation: A review of research about the Natura 2000 network
- The alignment of agricultural and nature conservation policies in the European Union
- Determination of ecological significance based on geostatistical assessment: a case study from the Slovak Natura 2000 protected area
- Routledge Handbook of the Study of the Commons
- Farmers' acceptance of results-based agri-environmental schemes: A German perspective
- Approaches to Identify the Value of Seminatural Habitats for Conservation Biological Control
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.